The process of updating the voter list across multiple Indian states is underway as part of the Special Intensive Revision, with the Election Commission of India shifting the entire system to a fully ...

It is a potentially deadly health condition that plagues more than half of all British adults. High cholesterol causes a sticky form of fat to build up in the arteries, blocking blood flow. Left ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Abbott Laboratories ABT1.77%increase; green up pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS 0.14%increase; green up pointing triangle in a deal valued at about ...

Shares of Exact Sciences (EXAS) continued to rise in the premarket on Thursday, adding ~18% after the cancer test maker agreed to be acquired by Abbott Laboratories (ABT) in an all-cash deal worth ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories agreed to acquire cancer-screening ...

North suburban-based Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow ...

Abbott's acquisition of Exact Sciences aims to improve cancer diagnostics and expand access to early detection and management. Exact Sciences' products, including Cologuard and Oncotype DX, will ...

Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics ...